TRDMT1

Across TCGA pan-cancer cohorts, TRDMT1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TRDMT1 data layer compared with 28 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher TRDMT1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TRDMT1 expression acts as an unfavorable survival marker, although some lineages such as ESCA show a favorable association.

LIHC, PRAD, and ESCA are the cancer types where TRDMT1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	II,III,IV	0.051	0.716	<.001	24	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
ESCA	DFS	Median	II,III,IV	1.000	0.290	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TRDMT1–LIHC (OS)

Open the LIHC breakdown →